On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer

This publication has 21 references indexed in Scilit:

• The effect of 2-2 difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity
  International Journal of Radiation Biology, 1999
• Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro
  International Journal of Radiation Oncology*Biology*Physics, 1998
• Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA doublestrand breaks as measured by pulsed-field gel electrophoresis
  International Journal of Radiation Biology, 1998
• Radiosensitizing Nucleosides
  JNCI Journal of the National Cancer Institute, 1996
• A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
  Annals of Oncology, 1996
• Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
  International Journal of Radiation Oncology*Biology*Physics, 1996
• Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event
  Cancer Chemotherapy and Pharmacology, 1995
• A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
  Journal of Clinical Oncology, 1991
• Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
  Cancer Chemotherapy and Pharmacology, 1991
• Intraoperative and external beam irradiation ± 5-FU for locally advanced pancreatic cancer
  International Journal of Radiation Oncology*Biology*Physics, 1987